Valuation: Valneva SE

Market Cap 400M 455M 372M 342M 641M 43.93B 652M 4.42B 1.73B 21.54B 1.71B 1.67B 74.56B P/E 2026 *
-5.75x
P/E 2027 * 5.56x
Enterprise Value 528M 600M 491M 451M 846M 57.98B 860M 5.84B 2.28B 28.43B 2.25B 2.21B 98.4B EV / Sales 2026 *
3.48x
EV / Sales 2027 * 1.57x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -
1 week-0.95%
Current month-5.02%
1 month-5.88%
3 months-5.88%
6 months-47.01%
Current year-43.01%
1 week 3.98
Extreme 3.98
4.32
1 month 3.98
Extreme 3.98
4.64
3 years 3.38
Extreme 3.38
14
5 years 3.38
Extreme 3.38
60.5
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 2021-07-28
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 2023-12-19
Director/Board Member 75 2013-03-06
Chairman 65 2023-12-19
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.95%-37.91%-68.72% 456M
+1.07%-3.49%-3.25%+12.87% 46.86B
+0.25%+1.65%+408.41%+629.49% 40.23B
-0.27%+4.45%+9.93%+66.92% 36.23B
+0.35%+0.87%+3.60%-8.81% 34.72B
+3.14%+1.02%+3.37%+38.15% 27.89B
-0.73%+11.84%+31.97%+143.53% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%+0.76%+8.50% 13.12B
-2.68%-2.49%-15.00%-31.68% 12.7B
Average +0.22%+0.83%+44.65%+87.81% 27.25B
Weighted average by Cap. +0.48%+0.91%+75.09%+136.23%

Financials

2026 *2027 *
Net sales 152M 173M 141M 130M 243M 16.66B 247M 1.68B 654M 8.17B 648M 634M 28.28B 294M 334M 273M 251M 471M 32.27B 479M 3.25B 1.27B 15.82B 1.25B 1.23B 54.76B
Net income -66.01M -75.02M -61.37M -56.32M -106M -7.24B -107M -729M -285M -3.55B -282M -276M -12.29B 70.5M 80.12M 65.54M 60.15M 113M 7.74B 115M 779M 304M 3.79B 301M 294M 13.13B
Net Debt 128M 145M 119M 109M 205M 14.05B 208M 1.41B 552M 6.89B 546M 534M 23.84B 60.02M 68.21M 55.8M 51.2M 96.13M 6.59B 97.7M 663M 259M 3.23B 256M 251M 11.18B
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
-
Date Price Change
26-07-24 €4.160 0.00%
26-07-23 €4.160 0.00%
26-07-22 €4.160 0.00%
26-07-21 €4.160 0.00%
26-07-20 €4.160 -0.95%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.111EUR
Average target price
5.233EUR
Spread / Average Target
+147.91%

Quarterly revenue - Rate of surprise